Cite
PCN2 Recurrences Avoided and Life Years Saved Attributable to Trastuzumab Use in HER2+ Early and Metastatic Breast Cancer in the United States.
MLA
Danese, M., et al. “PCN2 Recurrences Avoided and Life Years Saved Attributable to Trastuzumab Use in HER2+ Early and Metastatic Breast Cancer in the United States.” Value in Health, vol. 24, June 2021, p. S19. EBSCOhost, https://doi.org/10.1016/j.jval.2021.04.094.
APA
Danese, M., Doan, Q., Antao, V., & Sussell, J. (2021). PCN2 Recurrences Avoided and Life Years Saved Attributable to Trastuzumab Use in HER2+ Early and Metastatic Breast Cancer in the United States. Value in Health, 24, S19. https://doi.org/10.1016/j.jval.2021.04.094
Chicago
Danese, M., Q. Doan, V. Antao, and J. Sussell. 2021. “PCN2 Recurrences Avoided and Life Years Saved Attributable to Trastuzumab Use in HER2+ Early and Metastatic Breast Cancer in the United States.” Value in Health 24 (June): S19. doi:10.1016/j.jval.2021.04.094.